Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are human antidiabetic drugs that are increasingly used in equine practice for the management of hyperinsulinaemia and hyperinsulinaemia-associated laminitis. However, the understanding of SGLT2i use in horses is in its infancy compared to human medicine. This review article aims to briefly examine the literature in both species, highlighting current knowledge gaps, potential similarities in therapeutic outcomes and possible adverse effects.

T. Sundra, V. Matthews, P. Harris, D. Rendle

SGLT2 inhibitors: Exploring the effects in humans and horses

Sundra, T., Kelty, E., Rossi, G., Lester, G. & Rendle, D. (2024) Horse owner experiences and observations with the use of SGLT2i for the management of equine metabolic syndrome and hyperinsulinaemia-associated laminitis. Equine Veterinary Education, 00, 1–8. Available from: https://doi.org/10.1111/eve.13975

Horse owner experiences and observations with the use of SGLT2i for the management of equine metabolic syndrome and hyperinsulinaemia-associated laminitis

Sundra, T. Kelty, E. Rossi, G. Rendle, D. 2024 Retrospective assessment of the use of extended-release cabergoline in the management of equine pituitary pars intermedia dysfunction

Front. Vet. Sci., 06 March 2024 Sec. Veterinary Pharmacology and Toxicology
Volume 11 – 2024 | https://doi.org/10.3389/fvets.2024.1332337

Frontiers | Retrospective assessment of the use of extended-release cabergoline in the management of equine pituitary pars intermedia dysfunction (frontiersin.org)